Ali Crawford, Ph.D., Sr. Director of Scientific Research, has dedicated her career to tackling one of healthcare's most vexing challenges: rare disease. Her passion drives a relentless pursuit to unlock the genome's hidden secrets. At #ACMGMtg25, she presented updates on our constellation technology—pushing the boundaries of what's possible with short read genomes. Constellation represents a fundamental shift in how we interrogate the genome. This innovation brings library prep directly onto the flow cell and illuminates previously inaccessible genomic regions. For individuals searching for genetic answers, this means potentially life-changing insights. When constellation launches in 1H 2026, it promises to transform translational applications with unprecedented workflow simplicity and comprehensive genomic visibility. Learn more: https://bit.ly/3D7d2IM. #IlluminaProud #RareDisease #PrecisionMedicine
关于我们
At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
- 网站
-
https://www.illumina.com
Illumina的外部链接
- 所属行业
- 生物技术研究
- 规模
- 5,001-10,000 人
- 总部
- San Diego，CA
- 类型
- 上市公司
- 创立
- 1998
产品
![点击此处查看BaseSpace Clarity LIMS]()
BaseSpace Clarity LIMS
实验室信息管理系统 (LIMS)
BaseSpace Clarity LIMS is a laboratory information management system that helps genomics labs track samples and manage workflows for an optimized and efficient lab.
地点
Illumina员工
动态
-
Illumina转发了
Thank you to everyone who joined us at the Illumina Innovation Showcase last night at the Assn of Biomolecular Resource Facilities (ABRF) annual meeting. It’s always great to spend time with Core Directors to hear about the challenges they are facing and get feedback on our products and offerings. I was joined by Dr. Alvaro G. Hernandez, Ph.D., Director of DNA services Uni. of Illinois Urbana- Champaign, who gave a wonderful and insightful overview of his experience with the MiSeq i100 and the power and flexibility it brought to his lab, and Dr. Emily Parker of Illumina, who summarized the latest advances in our multiomic early access offerings ranging from Illumina Protein Prep, 5-base genome, single-cell, and our newest spatial platform. Illumina technology is designed to unlock deeper insights, power your multiomic discovery, and transform what’s possible in genomics and multiomics. Watch this space for more details from our innovation roadmap: https://lnkd.in/ghDy-J46 ?
-
-
At #ACMGMtg25 last week, we presented three posters that demonstrated the value of whole-genome sequencing (WGS) in interrogating challenging regions of the genome and providing rare genetic disease diagnoses. We sat down with Denise Perry, Sr. Director of Medical Genomics Laboratory Services, to talk about these posters, their findings, and the future of WGS: https://bit.ly/4iWKMYz
-
-
Chief Technology Officer, Steven Barnard, PhD compares multiomics to pointillist paintings, in which thousands of dots (or omics data points) come together to reveal a clearer image. Steve says, "unleashing the full potential of multiomics will transform everything, from the pace of scientific discovery and how quickly new drugs come to market to how we diagnose, detect, and treat life-threatening disease." Read Steve's perspective on how Illumina is uniquely positioned to bring multiomics to scale: https://bit.ly/41Y02xs
-
-
"Our 5-year plan: to decipher the effect of all variants in the human genome." - Kyle Kai-How Farh MD PhD, VP & Distinguished Scientist, AI at Illumina. At #ACMGMtg25, Kyle shared how his team is tackling the 99.9% of genetic variants currently classified as variants of unknown significance – so-called "dark DNA" – which are transforming rare disease diagnosis and drug discovery. By combining deep neural networks trained on data from 233 primate species with cutting-edge algorithms for non-coding sequences, Illumina models are outperforming all clinical benchmarks. With the ability to analyze whole genomes in minutes and interpret millions of variants through sophisticated AI models, we're accelerating the future of precision medicine. Together with the ACMG - American College of Medical Genetics and Genomics community, we're advancing genomic understanding and transforming patient care. #IlluminaProud #PrecisionMedicine #RareDisease
-
-
Jared Whitlock of Endpoints News has the exclusive on Illumina CEO Jacob Thaysen's view on the future of the industry – and why Illumina is poised to bring multiomics to scale.
At the headquarters of Illumina last week, CEO Jacob Thaysen bounded up a coiled staircase that mimics a DNA strand. The architectural flourish at the company’s campus is a representation of just how fundamental DNA sequencing has been to Illumina since it was founded in 1999. It has become a fixture in labs that use its gene-reading machines to discover drugs and diagnose patients. Thaysen took the CEO job 18 months ago with a mandate to make major changes. And in an overlook atop the building’s DNA-shaped staircase, he spoke with Endpoints News about his plans for Illumina beyond just genetics. While DNA is still core to Illumina’s business, Thaysen has bet that the company needs to expand further into what’s known as multiomics — a buzzy field that includes decoding proteins, RNA and other elements of biology. “Illumina has over the last 20 years really been driving the genomics revolution. The company is super proud about that,” Thaysen, 49, told Endpoints. “But what we’ve also seen is that biology is, of course, much more complicated.” Read more in my latest for Endpoints News. It tracks a push from Illumina and other companies into multiomics.
-
We're here at #ACMGMtg25 to share how our latest solutions are accelerating progress in rare disease, cancer care, and more. Visit our team at booth 409, and don't miss our featured sessions: https://bit.ly/4ixXH3v
-
The Alliance for Genomic Discovery has completed its initial goal of sequencing 250,000 whole genomes in just two years, creating one of the world’s largest and most comprehensive clinical genomic datasets of its kind. Convened?by Illumina and?NashBio, the consortium of biotech and biopharma organizations will utilize the insights to help accelerate the discovery?of novel drug targets. ? Illumina’s?Todd Christian?said: "AGD is delivering on its promise of unlocking new discoveries and we’re eager to build on this success with the addition of multiomic measurements to drive advances in therapeutic development.” ? Learn more:?https://lnkd.in/eZc3pQyy
-
Access to comprehensive biomarker testing is critical for patients facing non-small cell lung cancer (NSCLC). That's why we are proud to partner with LUNGevity Foundation and over 20 biopharma and diagnostic companies, professional societies, and patient advocacy organizations to equip healthcare decision-makers with unified evidence on the value of biomarker testing and precision medicine in NSCLC to improve patient outcomes. This new hub consolidates key resources and the latest research supporting biomarker testing using broad molecular panels to guide clinical decisions for patients with NSCLC: https://lnkd.in/g7im7fta
-
By 2025, all 55 National Public Health Institutes in Africa will have operational NGS capacity to help tackle infectious disease. We're excited to continue our collaboration with Africa CDC to enhance public health surveillance in Africa. Discover more: https://bit.ly/3XQJgir